Company / Accounts Receivable
Intellia Therapeutics, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$9.5M
FY2025
5-year range
$2.0M / $36.5M
FY2021-FY2025
Trend
+11.2%
vs FY2024
Sector context
#140 of 143
Health Care
What the data says
Among 143 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 2% for accounts receivable. Accounts Receivable has fluctuated over the past 10 years, ranging from $2M in FY2021 to $36M in FY2023.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +34.8%.
Declined from $36M to $9M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +36.0%
- 5-Year CAGR
- +34.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 143This company $9.5M Sector average $1.3B
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +34.8%, indicating consistent growth.
- In FY2025, accounts receivable increased 11.2% year-over-year.
- Ranks #140 out of 143 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5M | +11.2% |
| FY2024 | $8.5M | -76.6% |
| FY2023 | $36.5M | +867.5% |
| FY2022 | $3.8M | +85.5% |
| FY2021 | $2.0M | -4.6% |
| FY2020 | $2.1M | -53.9% |
| FY2019 | $4.6M | -38.8% |
| FY2018 | $7.5M | -27.9% |
| FY2017 | $10.5M | +62.2% |
| FY2016 | $6.5M | +545.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026